Taken together, the second-generation 20S proteasome inhibitors delanzomib, carfilzomib and ixazomib showed significant cytotoxic activity in GIST cells, which was independent of the KIT mutational status and imatinib sensitivity. Here, KIT is linked to gastrointestinal stromal tumor.